)
Visual
test
Sumitomo Pharma
Sumitomo Pharma (4506) investor relations material
Sumitomo Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary30 Jan, 2026
Executive summary
Q3 FY2025 revenue reached ¥347.7B, up 18.6% year-over-year, driven by strong North American product sales and milestone revenue from ORGOVYX®; overseas revenue rose 29.7%.
Core operating profit surged 408.5% to ¥109.4B, reflecting gains from the partial transfer of the Asian business and lower R&D expenses.
Net profit attributable to owners increased 407.5% to ¥107.7B, supported by gains from the Asian business transfer, with basic EPS at ¥271.03.
Financial highlights
Revenue increased by ¥54.6B year-over-year, with North America contributing significantly.
Gross profit increased 12.8% to ¥202.6B, while cost of sales rose 27.9%.
SG&A and R&D expenses decreased by ¥8.0B and ¥7.5B, respectively, due to business structure improvements; SG&A fell 6.4% to ¥116.4B, R&D fell 21.3% to ¥27.8B.
Operating profit rose to ¥109.8B from ¥13.2B, mainly due to a ¥49.0B gain on the Asian business transfer.
Net cash from operating activities was ¥42.3B, with cash and equivalents at ¥57.3B at period end.
Outlook and guidance
FY2025 revenue forecast is ¥429.0B, with core operating profit projected at ¥97.0B; focus remains on North American growth and product launches.
Regulatory approval for iPS cell-derived Parkinson's therapy in Japan targeted for FY2025.
Forex sensitivity: a ¥1 JPY depreciation is expected to increase revenue by ¥2.2B and core operating profit by ¥0.4B.
Core profit growth excluding one-time gains?
What drives NA growth vs Asia revenue decline?
Strategic role of new regen med ventures & pipeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 6723
AI and industrial demand drive growth, timing business sold, inventory targets raised. - 032640
Net profit rose 61.9% on strong mobile and enterprise growth, with AIDC and AI driving expansion. - S68
Record revenue, robust margins, and strong IPO pipeline highlight broad-based growth. - 6417
Strong pachinko sales drove revenue growth, with major treasury stock cancellation planned. - BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue.
Next Sumitomo Pharma earnings date
Q4 202613 May, 2026
Sumitomo Pharma
Next Sumitomo Pharma earnings date
Q4 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription drugs and medical solutions. The company focuses on therapeutic areas such as psychiatry, neurology, oncology, and infectious diseases. The company is headquartered in Osaka, Japan, and its shares are listed on the Tokyo Stock Exchange (TSE).
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage